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Objective: This population-based longitudinal study aimed to investigate trends in use of
inhaled corticosteroids (ICS) and determinants of ICS use in young Danish adults with asthma.
Methods: 106 757 users, aged 18e44 years, of anti-asthmatic drugs were identified in the
Danish Register of Medical Product Statistics during 1997e2006. One year prevalences of ICS
use were calculated in categories of gender, age, and annual consumption of inhaled beta-
2-agonists (IBA) in defined daily doses (DDD) per year. Determinants of ICS use were estimated
by logistic regression models.
Results: Theoneyear prevalenceof ICS usewas constant, approximately 64%, during 1997e2000.
An annual increase was observed from 67% in 2001 to 77% in 2006. This trend also existed when
stratifying on gender, age and IBA use. Using 1997 as baseline, the adjusted odds ratios (ORs)
of ICS use in 2000 was 0.98 (95% CI 0.96e1.01) compared to 1.12 (95% CI 1.09e1.15) in 2001,
and 1.81 (95% CI 1.75e1.87) in 2006. Other determinants of high ICS use were female gender,
young age, and high annual IBA consumption. Among those using at least 400 DDD of IBA per year
(corresponding to 4.4 powder inhalations daily), nearly 20% had no ICS prescriptions in 2006.
Conclusion: Treatment with ICS among young Danish adult asthmatics has increased since 2001.
This apparent improvement was associated with the introduction of fixed dose combinationf Southern Denmark, Faculty of Health Sciences, Institute of Public Health, Research Unit for General
000 Odense C, Denmark. Tel.: þ45 6550 3968; fax: þ45 6550 3980.
.sdu.dk (J.R. Davidsen).
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1818 J.R. Davidsen et al.inhalers with ICS and inhaled long-acting beta-2-agonists. However, there is still room for
improvement.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Asthma treatment aims to achieve and maintain symptom
control by suppressing the underlying inflammation of the
asthmatic airways.1,2 Inhaled corticosteroids (ICS) have
proved to be the most effective anti-inflammatory drugs in
treatment of persistent asthma,3 thus comprising the
mainstay as maintenance therapy.1,2,4 However, ICS are not
used optimally in clinical practice.5e8 A common problem is
that asthma patients who deteriorate increase their use of
reliever therapy with bronchodilators instead of intensi-
fying controller therapy with ICS.6,9 Previous studies have
used the percentage of ICS users among asthma patients as
a quality indicator for asthma treatment.10e13 Among
asthma patients with frequent use of inhaled beta-2-
agonists (IBA) only 10e20% were sufficiently treated with
ICS and 20e35% did not use ICS at all.10,12,13 This under
treatment of the airway inflammation is a major problem as
it is associated with reduced asthma control, including an
increased number of exacerbations, lung function impair-
ment, and reduced quality of life.14,15
Fixed dose combination (FDC) inhalers with ICS and
inhaled long-acting beta-2-agonists (LABA) are an
accepted treatment option to patients with moderate and
severe persistent asthma,1,4 but the influence of these
FDCs on the overall trend of ICS use has not previously
been reported.
Our aim was to assess whether treatment with ICS in
a population of young adult asthma patients had improved
over time, taking the introduction of FDCs into account,
and to analyse determinants of ICS treatment at an indi-
vidual level with respect to time trends, gender, age,
consumption of inhaled beta-2-agonists (IBA), and use of
different anti-asthmatic drugs. We used population-based
data from nationwide registers over a 10 year period.Methods and materials
Study design
By use of population-based registers we conducted an
observational longitudinal study including all young adult
users of anti-asthmatic drugs in Denmark during
1997e2006. Data were analysed as repeated annual cross-
sections.
Data sources
Data were retrieved from two registers in Statistics
Denmark, the Demographic Register and the Register of
Medical Product Statistics (RMPS). In brief, Statistics
Denmark is a governmental institution collecting electronic
records for a broad spectrum of statistical and scientific
purposes, and it is possible to retrieve detailed longitudinalinformation at an individual level for the entire Danish
population (5.27 million in 1997 and 5.43 million in 2006).16
Data on pharmacotherapy were extracted from RMPS
that comprises information on every medical product sold
on prescription by Danish pharmacies since 1994. Each
prescription record includes the patient’s identifier, the
identification code of the prescriber, the date of
dispensing, the brand name, the manufacturer, quantity,
form of the drug, code of reimbursement etc. Information
on substances and quantities are classified according to
World Health Organisation (WHO) anatomicalether-
apeuticechemical (ATC) system and defined daily doses
(DDD) methodology.17 We obtained data on gender, year of
birth, residence, and date of death, or of migrations from
the Demographic Register. We used the unique civil regis-
tration number (CRN) to link data between registers.
Study subjects
All subjects who had redeemed drugs with ATC code R03
(drugs for obstructive airway diseases) during 1 January
1997 e 31 December 2006 were identified. We analysed
annual cross-sections of this population with 1 January as
index date. Using the demographic data, we included only
subjects alive and resident in Denmark during the past year.
The annual group of asthma patients was defined for
each index date as all subjects who fulfilled the following
inclusion criteria: 1) age 18e44 years, 2) 2 redeemed
prescriptions on inhaled beta-2-agonists (IBA) within 365
days before the index date, and 3) current IBA use
defined as 1 redeemed prescription of IBA 180 days
before the index date. IBA referred to inhaled short-
acting beta-2-agonists (SABA, ATC R03AC02, R03AC03,
R03AC04, and R03AC05), LABA (ATC R03AC12, and
R03AC13), fixed combinations of SABA with anticholiner-
gics (ATC R03AK03 and R03AK04), or LABA with ICS (ATC
R03AK06 and R03AK07). The inclusion criteria implied
a change in the annual group of eligible asthma patients,
since age, number of IBA prescriptions, and current IBA
use at each index date influenced inclusion or exclusion
that particular year (Fig. 1). A subject could be included
on multiple index dates, if he or she fulfilled the inclusion
criteria.
Data analysis
Data were analysed as annual cross-sections during the
observation period. Our outcome was use of ICS, defined as
1 redeemed prescription of ICS during the year preceding
the index date. ICS referred to ICS in non-combination
inhalers (ATC R03BA01, R03BA02, R03BA03, R03BA05, and
R03BA07), or FDCs with ICS and LABA (ATC R03AK06
and R03AK07). Thus, use of FDCs was considered both as IBA
and ICS use. The one year prevalence of ICS use was
calculated corresponding to each index date, with the
6-21- 0
1 January = index date 
Repeated use:
2 IBA prescriptions / 12 months before index date
Current use:
1 IBA prescription / 6 months before index date
ICS use:
1 ICS prescription / 12 months before index date
Age restriction:
18-44 years
Inclusion
(proxy for 
diagnosis)
Proxy for
ICS use
Months before index date in
a particular observation year
Figure 1 Criteria for inclusion. 1 prescription on ICS/year was used as a proxy for appropriate asthma treatment. Abbrevia-
tions: IBA Z inhaled beta-2-agonists. ICS Z inhaled corticosteroids.
Increased ICS use among young adult asthmatics 1819numerator representing the number of ICS users and the
denominator the number of IBA users according to inclusion
criteria. We stratified subjects into three age categories:
18e24 years, 25e34 years, and 35e44 years. We cat-
egorised subjects according to their annual average IBA
consumption in DDD (1e99, 100e199, 200e399, and 400
DDD/year). It has previously been shown that ICS use
depends on IBA consumption.10 The DDD represents the
assumed average maintenance dose per day for a drug used
for its main indication in adults.17 As an example, the DDD
for inhaled terbutaline is 2.0 mg. Thus, a person using 400
DDD/year would have an average use of 4.38 inhalations
daily with a 0.5 mg inhaler device. The DDD is not a dose
recommendation, but should be seen as a common yard-
stick to express quantising for drugs that have different
potency. DDDs for the most frequently used IBAs in our
material are presented in Table 1.
To analyse variables associated with ICS use, crude and
adjusted odds ratios (ORs) with 95% confidence intervals
(CIs) were estimated by means of logistic regression
models. We adjusted for repeated measurements of the
same subject by clustering on CRN. Our primary indepen-
dent variables were calendar years reflecting possible time
trends in ICS use. Other independent variables considered
as factors associated with ICS use and potentialTable 1 Defined daily doses (DDD) of the most frequently use
Denmark during 1997e2006.
ATC-code Drug
R03AC02 Salbutamol
R03AC03 Terbutaline
R03AC04 Fenoterol
R03AC12 Salmeterol
R03AC13 Formoterol
R03AK06 Salmeterol/Fluticasone
R03AK07 Formoterol/Budesonide
R03AK03 Fenoterol/Ipratropium
R03AK04 Salbutamol/Ipratropiumconfounders of a time trend were gender, age category, IBA
use category, and prevalent use of other anti-asthmatic or
asthma-related drugs expected to be associated with
asthma and thus possible determinants of ICS use. Preva-
lent use of a particular drug was defined as at least one
redeemed prescription during the year preceding the index
date. Drugs included were systemic glucocorticosteroids
(ATC H02AB), leukotriene receptor antagonists (ATC
R03DC), intranasal drugs for rhinitis (ATC R01A), drugs for
specific immune therapy (ATC V01), inhaled short-acting
anticholinergics (ATC R03BB01 and R03BB02), oral long-
acting beta-2-agonists (ATC R03CC), oral methylxanthines
(ATC R03DA), and oral chromones (ATC R03BC). Anti-IgE
(ATC R03DX) was not included as this drug category has
restricted supply to hospitals, thus no individual records
were observed in our data. Also inhaled long-acting anti-
cholinergics (ATC R03BB04) were not included, as this drug
was introduced in 2002 with COPD as the primary indica-
tion. Analyses for interactions between independent vari-
ables were performed, but only the interaction between
gender and IBA use category was considered clinically
important. In the final analysis, the ORs were adjusted for
this interaction and the independent variables listed above.
All analyses were performed using Stata Release 10.1
(StataCorp, College Station, TX, USA).d inhaled beta-2-agonists by young adult asthma patients in
DDD
0.8 mg (Inhaled)
10.0 mg (Nebulized)
2.0 mg (Inhaled)
20.0 mg (Nebulized)
0.6 mg (Inhaled)
4.0 mg (Nebulized)
0.1 mg (Inhaled)
24.0 mg (Inhaled)
0.1 mg/0.6 mg (Inhaled)
24.0 mg/0.8 mg (Inhaled)
0.6 mg/0.12 mg (Inhaled)
4.0 mg/0.3 mg (Nebulized)
0.8 mg/0.12 mg (Inhaled)
10.0 mg/0.3 mg (Nebulized)
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in Denmark. Statistics Denmark and the Danish Medicines
Agency gave permission to data access.Results
Between 1997 and 2006 a total of 106 757 subjects, 58 005
(54.3%) women, met the inclusion criteria, corresponding to
350 070 observations. This way, eligible subjects were
included on average 3.3 times during the observation
period. At the year of first inclusion, the mean age for
women was 31.3 (SD 8.3) years versus 30.5 (SD 8.3) years for
men and the proportion of subjects in age category 18e24
years, 25e34 years, and 35e44 years was 27.9%, 32.7%, and
39.4%, respectively.
Trends of ICS use
ICS was prescribed for 82 269 subjects (77%). The one year
prevalence of ICS use was roughly constant during
1997e2000, approximately 64%, but a gradual increase was
observed from 67% in 2001 to 77% in 2006.
Fig. 2 shows the one year prevalence of ICS use stratified
by age, gender, and calendar year. Women had a consis-
tently higher one year prevalence of ICS use in all age
groups. In the age category 35e44 years, the one year
prevalence of ICS use in women versus men was 70.2% (95%
CI 69.2e71.3) and 63.9% (95% CI 62.7e65.1) in 1997
compared to 80.6% (95% CI 79.8e81.4) and 73.5% (95% CI
72.6e74.5) in 2006. In both genders, subjects in age cate-
gory 35e44 years had the highest one year prevalence of
ICS use from 1997 to 2000, but from 2001 to 2006 the
highest one year prevalence of ICS use was found in the age
category 18e24 years. Subjects aged 25e34 years had the
lowest one year prevalence of ICS use at all observation
years, irrespective of gender.Figure 2 Prevalence of ICS use in different age categories st
1997e2006. Hollow symbols/solid symbols Z women/men. AbbrevFig. 3 shows theone year prevalence of ICS use in different
categories of IBA users by quantity. Again, a constant one
year prevalence of ICS use was seen during 1997e2000 fol-
lowed by an increase in all groups of IBA users. The highest
one year prevalence of ICS usewas found in the twoupper IBA
use categories (200e399, and400 DDD/year), but the most
pronounced increase was seen in the lowest IBA use category
(1e99 DDD/year) from 52.5% (CI 95% 51.4e53.7) in 2000 to
71.8 (CI 95% 70.7e72.8) in 2006.
Fig. 4 shows ICS users categorised into users of only ICS
non-combination inhalers, users of only FDCs with ICS and
LABA, and users of both treatment options. In 1997e1999 ICS
use was limited to non-combination inhalers, but from 2000
the proportion of non-combination users decreased concur-
rently with a rapid increase in FDC users from 3.5% in 2000 to
48.2% in 2006. In 2006 the proportion of FDC users exceeded
the proportion of non-combination users (42.6%). Concur-
rently, users of both combination and non-combination
products also increased from 4.9% in 2000 to 9.3% in 2006.
Determinants of ICS use
Table 2 shows the determinants of ICS use. We found
increasing ORs for all calendar years from year 2001e2006.
No time trend was found for year 1998e2000, neither in the
crude nor in the adjusted model. We found a clear effect of
gender as men had lower odds of ICS use compared to
women (adjusted OR 0.81, 95% CI 0.78e0.85). Subjects with
a high annual consumption of IBA had higher ORs compared
to subjects with a low annual IBA consumption. Men had
consistently lower ORs in all IBA use categories compared to
women. Furthermore, we found high ORs for prevalent use
of leukotriene receptor antagonists, adjusted OR 3.53 (95%
CI 3.25e3.84), and drugs for specific immune therapy,
adjusted OR 2.32 (95% CI 2.11e2.56). Use of systemic glu-
cocorticosteroids, intranasal drugs for rhinitis, short-acting
anticholinergics, oral beta-2-agonists, and methylxanthinesratified on gender each year during the observation period
iations: ICS Z inhaled corticosteroids.
Figure 3 Prevalence of ICS use in different categories of IBA use each year during the observation period 1997e2006. IBA use in
defined daily doses during 1 year (DDD/year). Abbreviations: IBA Z inhaled beta-2-agonists. ICS Z inhaled corticosteroids.
Increased ICS use among young adult asthmatics 1821also showed positive association with ICS use. A negative
association with ICS use was solely found with use of
chromones, adjusted OR 0.60 (95% CI 0.45e0.78).
Discussion
Findings and comparison with other studies
The key findings of this study are an increasing one year
prevalence of ICS use among young Danish adults with
asthma from 2001 to 2006, concurrently with a pronounced
increase in the use of FDCs with ICS and LABA. FourFigure 4 Proportion of ICS users categorised into users of only I
combinations with ICS and LABA (ICS-FDC), and users of both treat
1997e2006. Abbreviations: ICS Z inhaled corticosteroids. LABA Zvariables stood out as determinants of ICS use: Calendar
year from year 2001, high IBA use categories, female
gender, and low age category. To our knowledge, this is the
first longitudinal study that analyses the impact of FDC
introduction on asthma patients’ ICS use.18e21
One explanation for the sudden increase in ICS use seems
obvious. In 2000 and 2001, FDCs with fluticasone/salmeterol
andbudesonide/formoterolwere introducedrespectively,and
extensively marketed in Denmark to patients with persistent
asthma who were not fully controlled on low doses of ICS.
There is good evidence that FDCs of budesonide/formoterol in
one inhaler as bothmaintenance and reliever therapy improveCS non-combination inhalers (ICS-NC), users of only fixed dose
ment options (ICS-NC þ ICS-FDC) during the observation period
long-acting inhaled beta-2-agonists.
Table 2 Crude and adjusted odds ratios (ORs) for different determinants associated with use of inhaled corticosteroids (ICS).
Determinants for ICS use Prevalent usersa Crudeb Adjustedb,c
N (%) OR (95% CI) OR (95% CI)
Yeard 1997 33 819 (31.7) 1.00 1.00
1998 35 335 (33.1) 1.01 (0.99e1.03) 1.00 (0.98e1.03)
1999 35 554 (33.3) 1.00 (0.98e1.03) 0.98 (0.95e1.01)
2000 33 445 (31.4) 1.00 (0.97e1.03) 0.98 (0.96e1.01)
2001 33 687 (31.6) 1.14 (1.11e1.17) 1.12 (1.09e1.15)
2002 34 519 (32.3) 1.29 (1.25e1.33) 1.26 (1.23e1.30)
2003 35 035 (32.8) 1.40 (1.36e1.44) 1.39 (1.34e1.43)
2004 36 463 (34.2) 1.56 (1.52e1.61) 1.56 (1.51e1.61)
2005 35 819 (33.6) 1.68 (1.63e1.73) 1.66 (1.61e1.71)
2006 36 394 (34.1) 1.83 (1.77e1.88) 1.81 (1.75e1.87)
Gender Women 1.00 1.00
Men 0.66 (0.64e0.68) 0.81 (0.78e0.85)
Age (Years) 18e24 1.00 1.00
25e34 0.83 (0.81e0.86) 0.79 (0.76e0.81)
35e44 1.06 (1.03e1.09) 0.92 (0.89e0.95)
IBA use, women (DDD/year) 1e99 1.00 1.00
100e199 1.38 (1.34e1.43) 1.36 (1.32e1.41)
200e399 2.38 (2.28e2.49) 2.30 (2.20e2.40)
400 2.68 (2.53e2.84) 2.43 (2.30e2.58)
IBA use, men (DDD/year) 1e99 1.00 1.00
100e199 1.21 (1.17e1.26) 1.22 (1.17e1.26)
200e399 1.64 (1.57e1.71) 1.63 (1.56e1.70)
 400 1.62 (1.54e1.70) 1.57 (1.50e1.66)
Systemic glucocorticosteroids No 1.00 1.00
Yes 23 185 (21.72) 1.81 (1.75e1.87) 1.53 (1.47e1.58)
Leukotriene receptor antagonists No 1.00 1.00
Yes 7621 (7.14) 4.86 (4.47e5.27) 3.53 (3.25e3.84)
Intranasal drugs for rhinitis No 1.00 1.00
Yes 32 075 (30.04) 2.15 (2.09e2.22) 2.03 (1.97e2.09)
Drugs for specific immune therapy No 1.00 1.00
Yes 2866 (2.68) 2.67 (2.42e2.94) 2.32 (2.11e2.56)
Short-acting anticholinergics No 1.00 1.00
Yes 728 (0.68) 2.32 (1.87e2.88) 1.63 (1.30e2.04)
Oral beta-2-agonists No 1.00 1.00
Yes 5030 (4.71) 1.26 (1.18e1.36) 1.09 (1.02e1.18)
Methylxanthines No 1.00 1.00
Yes 2587 (2.42) 1.81 (1.62e2.01) 1.44 (1.29e1.61)
Chromones No 1.00 1.00
Yes 297 (0.28) 0.63 (0.48e0.83) 0.60 (0.45e0.78)
a For each calendar year the number of included subjects is presented in percentages of the total number of included subjects for the
entire observation period (N = 106 757). Number and percentages of users of specific anti-asthmatic drug categories are presented for
the entire observation period.
b Lowest IBA use category for each gender, lowest age band, female gender, calendar year 1997, and non-use of specific anti-asthmatic
drug categories were considered as references.
c Adjusted for IBA use categories, gender, interaction between IBA categories and gender, age categories, calendar years (time trend),
and ever use of specific anti-asthmatic drug categories.
d Tests for time trends for 1997e2000 and 2001e2006 were pZ 0.189 and p < 0.0001, respectively. Abbreviations: IBAZ inhaled beta-
2-agonists.
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use of budesonide and formoterol in combination with SABA
reliever therapy.22e24 The budesonide/formoterol treatment
approach is now implemented in GINA guidelines.1,9 In 2006,
FDCs represented 48.2% of ICS use which is consistent with
reportedfindings fromSweden in2007 (46%).25Additionally, an
intensified focus on factors associated with appropriatetreatment such as improved diagnostics, improved patient
education and access to specific information knowledge
through the media should be considered.21,26
High annual IBA consumption was associated with ICS use
in both genders, though men seemed to be less responsive
to IBA consumption, having consistently lower ORs in all IBA
use categories compared to women. The more frequent ICS
Increased ICS use among young adult asthmatics 1823use in women has been reported in some,27 but not all28e30
studies on gender differences in ICS use. Some of the
inconsistencies in relation to our finding may be lack of
standardisation due to definition of ICS use, differences in
study design, and inclusion criteria. The most pronounced
increase in ICS use was seen in the age category 18e24
years. This apparently contradicts findings by Diette et al.
who reported young age as a determinant for ICS under-
use.31 However, this study was performed before the
introduction of the FDCs. Besides this study, we are not
aware of other major reports on the age dependency of ICS
use among young adults with asthma.
Strengths and limitations
The main strength of this study is its population-based
approach. The use of national register data with a high
completeness minimises selection bias and avoids recall
bias. Furthermore, we used age restriction in our study
design to avoid inclusion of COPD patients, where inhaled
beta-2-agonists are also indicated, but where ICS use is not
imperative. An important limitation was lack of diagnosis
and indication for treatment. Instead, we used a proxy for
the asthma diagnosis. A Dutch validation study supported
our proxy for asthma diagnosis requiring at least two IBA
redemptions per year.32
We used the annual IBA use as a determinant of ICS
use. As IBA we included SABA, fixed combinations of SABA
and anticholinergics, LABA, and the LABA component of
FDCs for two reasons. Firstly, before introduction of FDCs
containing LABA and ICS, subjects could use the two
drugs concomitantly by two different prescriptions.
Secondly, the LABA formoterol is approved for reliever
therapy to patients with moderate to severe persistent
asthma, because of its rapid onset of action as a bron-
chodilator.1 Including all these under the IBA heading
enabled us to compare IBA use consistently for all years
in the analysis.
We considered 1 redeemed prescription of ICS the year
preceding an index date as indicative of ICS use. By not
requiring current ICS use or looking at the adequacy of ICS
dose, we might have overestimated the number of appro-
priately treated patients with persistent asthma. The main
purpose of the study was to estimate the overall use of ICS
regardless of the inhaler. Therefore we have not distin-
guished between ICS non-combination inhalers and FDCs.
Furthermore, our analysis did not account for possible over
treatment with ICS or FDCs. Lastly, as we used a register-
based approach our study design could not account for
some potential confounders that might affect ICS use
among asthma patients, e.g. smoking.
Conclusion
This study demonstrates that treatment with ICS among
young Danish adults with asthma has increased since 2001
and that this apparent improvement in the quality of asthma
treatment primarily was due to introduction of FDCs with ICS
and LABA. However, some 20% of subjects with high IBA
consumption during 2001e2006 were not prescribed ICS
indicating that there is still room for improvement. Also, itappears that the largest improvement in ICS use was seen in
the categories of low IBA use. Nonetheless, when comparing
to other studies using quality indicators based on prescrip-
tion data to assess appropriateness of asthma treatment,
our results suggest that the level of ICS prescribing in
Denmark is high compared to other countries.12,13 To
increase use of ICS there is a need to identify subgroups
deserving special attention. Future studies should investi-
gate other potential determinants of suboptimal asthma
treatment such as socioeconomic status, price of medicine,
self-experienced side effects to ICS and perceptions of and
beliefs in maintenance therapy with ICS. Furthermore, on
the basis of our findings it would be interesting to explore
whether an increased use of ICS was linked to lower rates of
asthma hospitalization and asthma death.
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